Advaxis Announces 1-for-125 Reverse Stock Split and Decrease in Authorized Shares of Common Stock Advaxis, Inc., , a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today a 1-for-125 reverse stock split of its common stock and a decrease in the number of its authorized shares of common stock from 1,000,000,000 to 25,000,000.
July 15, 2013 - Business Wire via Yahoo! Finance